US Patent

US10668040 — Treatment of urea cycle disorders in neonates and infants

Method of Use · Assigned to Horizon Therapeutics LLC · Expires 2030-09-22 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of safely administering nitrogen scavenging drugs like glycerol phenylbutyrate to infants and toddlers with urea cycle disorders.

USPTO Abstract

Nitrogen scavenging drugs such as glycerol phenylbutyrate can be administered safely to infants and toddlers with urea cycle disorders by adjusting the dosage based on one or more biomarkers selected from the group consisting of urinary-PAGN and plasma PAA:PAGN ratio.

Drugs covered by this patent

Ravicti (GLYCEROL PHENYLBUTYRATE) · Horizon Therap Us

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1816`	—	Ravicti

Patent Metadata

Patent number: US10668040
Jurisdiction: US
Classification: Method of Use
Expires: 2030-09-22
Drug substance claim: No
Drug product claim: No
Assignee: Horizon Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.